Skip to main content

Table 1 Demographics and other key patient characteristics

From: Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial

Characteristic

nVNS (n = 120)

Sham (n = 123)

Total (N = 243)

Age, mean (SD), y

38.8 (11.0)

39.6 (11.8)

39.2 (11.4)

Female sex, No. (%)

95 (79.2)

91 (74.0)

186 (76.5)

Diagnosis, No. (%)

 Migraine with aura

8 (6.7)

9 (7.3)

17 (7.0)

 Migraine without aura

112 (93.3)

114 (92.7)

226 (93.0)

Current preventive medication use, No. (%)

42 (35.0)

35 (28.5)

77 (31.7)

No. of acute medication days per mo,a mean (SD)

5.6 (1.7)

5.3 (1.7)

5.5 (1.7)

Attack severity at onset for all treated attacks in DB period, No. (%)

n = 359 b

n = 329 b

NA

 Mild

113 (31.5)

105 (31.9)

 Moderate

156 (43.5)

166 (50.5)

 Severe

90 (25.1)

58 (17.6)

Attack severity at onset for first treated attack in DB period, No. (%)

n = 119 b

n = 119 b

NA

 Mild

40 (33.6)

46 (38.7)

 Moderate

51 (42.9)

55 (46.2)

 Severe

28 (23.5)

18 (15.1)

 
  1. Tassorelli C, Grazzi L, de Tommaso M, et al. Non-invasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology. 2018;91(4):e364−e373
  2. Abbreviations: DB Double-blind, NA Not applicable, nVNS Non-invasive vagus nerve stimulation, SD Standard deviation
  3. aNo. of days the patient typically takes acute migraine medication per month. b Patients with no reported baseline severity were excluded from this analysis